Central Institute for Experimental Medicine and Life Science is private and independent Non-profit institute, founded in 1952 with the aim of contributing to medical care and medical science based on animal experiments, which are considered to be quite rare globally.

We have earned an excellent reputation in the research, development and commercialization of the world's most advanced laboratory animals and germ-free animal-related technologies that provide support therefor, as well as other technologies such as monitoring tests, pathology tests, genetic modification, developmental engineering, and image analysis, and cooperate with universities and research institutions in Japan and other countries, international public organizations such as WHO, NIH, FDA, and NIBSC, and business enterprises.

Working with WHO, we played a very important role and achieved satisfactory results in a polio eradication program, in the establishment of muscular dystrophy therapeutics, in the establishment of procedures to demonstrate the safety of regenerative and cellular medicine, and in the development of various pharmaceuticals for cancers and other diseases. We aim to do something others have never done, commercialize work that has been started even if it takes 20 to 30 years, and contribute to the health of human-beings of the world as a world-class system. We perform cutting-edge original research, collaborate with world-leading researchers, universities, business enterprises, and regulatory agents, and continue research and development activities to contribute to solving issues which the world today faces, such as cancers, life-threatening diseases of the central nervous system such as Alzheimer's disease, from rare diseases to familiar allergic diseases, and the development of fertility treatment technologies to address declining birthrate and aging population.

On the other hand, as an independent research institute, it is inevitable that we independently raise funds for our research. We need to expand the structure to commercialize the research outcomes by entering into licensing agreements with business enterprises, and collect royalties to fund further research. While being a research institute, there is a need for development activities not only for research but also for commercialization, diffusion and sales expansion activities in cooperation with licensees in Europe, the United States, China, and other countries, and a consulting business. This unique business model is our quintessence. We think that research outcomes become a public asset when they are applied in real-world settings and are widely used by people all over the world, contributing to the health of human-beings.

We, CIEM, always have a sense of tension, break the common sense, and keep challenging while keeping the essence in sight.

We would highly appreciate your continued support and cooperation.

Central Institute for Experimental Medicine and Life Science
Chairman　Ryuta Nomura